Suven's Masupirdine Data Could Decide Two Decades of R&D

Suven Life Sciences is staring at a binary moment. The company’s lead drug candidate, Masupirdine, for agitation in Alzheimer’s dementia, is in phase 3 trials. Data readout is expected by the end of the March quarter. That result will determine whether nearly two decades of central nervous system research and about ₹4,000 crore of investment produce a commercial product or a dead end.

Chief executive Venkat Jasti is blunt about the odds. “As of now, it is zero,” he said. “Until the check is in the bank, you cannot count on anything in this business.”

Suven completed a ₹248.8 crore tranche of its 2025 preferential fundraising on 8 July after all 17 non-promoter investors exercised their warrants, issuing 18.6 million equity shares. The company raised roughly ₹858 crore through the full issue. It also announced plans to set up a wholly owned Singapore subsidiary, a move that signals preparation for licensing or co-development partnerships with international drugmakers.

The stock has rallied 117% over the past six months to ₹326 on the National Stock Exchange, reflecting investor optimism about the pipeline. The risk in CNS drug discovery is extreme, Jasti said. The success rate for CNS trials is about 0.5% because outcome measures rely on subjective rating scales rather than quantitative biomarkers.

“The reason is that for all other diseases, you have quantitative measurements of the outcomes,” he said. “How do you measure memory? How do you measure pain?”

Suven’s pipeline includes three other candidates. A narcolepsy drug is also in phase 3. Usmarapride, for cognitive impairment in Parkinson’s disease, and Ropanicant, for major depressive disorder, are in phase 2. In June, the company reported positive top-line proof-of-concept results for Ropanicant.

Vishal Manchanda, pharma analyst at Systematix Group, said the market opportunity is large but the bar is high. “They don’t need to just be successful in phase three trials, they have to be adequately successful,” he said. “They have to beat the benchmarks that are already set.”

Big pharma has shown renewed appetite for CNS therapies. Bristol Myers Squibb’s schizophrenia drug Cobenfy, approved in 2024, is projected to generate more than $3 billion in annual sales by the early 2030s. Eli Lilly’s early Alzheimer’s therapy Kisunla, also approved in 2024, is expected to become a multi-billion-dollar product as uptake accelerates. In January 2026, Novartis signed a $1.7 billion deal with SciNeuro Pharmaceuticals for Alzheimer’s antibody treatments. In 2025, Johnson & Johnson acquired Intra-Cellular Therapies for about $15 billion, largely to gain access to its depression drug Caplyta and its neuroscience pipeline.

Jasti said big pharma has become more risk-averse, waiting until a drug is near market before entering. That forced Suven to fund phase 3 trials itself, a path Indian biotechs rarely take. “We had to build up the knowledge and the infrastructure. And of course, we had to have the staying power and the perseverance to proceed further,” he said.

Suven’s revenue for FY26 was ₹210.45 crore, with a net loss of ₹2,763.44 crore, driven by R&D and operational costs of ₹2,916 crore. The company’s research team was built in-house, largely with fresh recruits. Jasti said he hired a handful of senior scientists from other therapy areas and trained new graduates, avoiding experienced hires who might carry a “generics mindset.”

For the two big pharma names most relevant to the CNS space, AlphaScala ratings show Bristol-Myers Squibb with a score of 65 out of 100 and Johnson & Johnson at 64, both in the “Moderate” label range. The scores reflect the risk and opportunity in the sector, where success depends on phase 3 data and regulatory approval.

Jasti characterized drug discovery as a “zero to one sum game.” He believed one big success would shift the mindset of Indian investors toward novel drug research. For Suven, that success must come from the Masupirdine data in the next few months.